125 related articles for article (PubMed ID: 32060361)
1. Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients.
Goroshchuk O; Vidarsdottir L; Björklund AC; Hamil AS; Kolosenko I; Dowdy SF; Palm-Apergi C
Sci Rep; 2020 Feb; 10(1):2688. PubMed ID: 32060361
[TBL] [Abstract][Full Text] [Related]
2. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
Kolosenko I; Edsbäcker E; Björklund AC; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
J Control Release; 2017 Sep; 261():199-206. PubMed ID: 28684168
[TBL] [Abstract][Full Text] [Related]
3. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Hartsink-Segers SA; Exalto C; Allen M; Williamson D; Clifford SC; Horstmann M; Caron HN; Pieters R; Den Boer ML
Haematologica; 2013 Oct; 98(10):1539-46. PubMed ID: 23753023
[TBL] [Abstract][Full Text] [Related]
6. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.
Oliveira JC; Pezuk JA; Brassesco MS; Morales AG; Queiroz RG; Scrideli CA; Tone LG
Pediatr Blood Cancer; 2014 Jul; 61(7):1227-31. PubMed ID: 24519995
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.
Wang NN; Li ZH; Zhao H; Tao YF; Xu LX; Lu J; Cao L; Du XJ; Sun LC; Zhao WL; Xiao PF; Fang F; Su GH; Li YH; Li G; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Ni J; Wang J; Hu SY; Zhu XM; Feng X; Pan J
Int J Mol Sci; 2015 Jan; 16(1):1266-92. PubMed ID: 25574601
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinases and acute leukemia.
Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
[TBL] [Abstract][Full Text] [Related]
10. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
[TBL] [Abstract][Full Text] [Related]
11. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.
Kannan S; Aitken MJL; Herbrich SM; Golfman LS; Hall MG; Mak DH; Burks JK; Song G; Konopleva M; Mullighan CG; Chandra J; Zweidler-McKay PA
Mol Cancer Ther; 2019 Sep; 18(9):1615-1627. PubMed ID: 31227645
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
13. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.
Uckun FM; Ozer Z; Qazi S; Tuel-Ahlgren L; Mao C
Br J Haematol; 2010 Mar; 148(5):714-25. PubMed ID: 19912216
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
Hu K; Lee C; Qiu D; Fotovati A; Davies A; Abu-Ali S; Wai D; Lawlor ER; Triche TJ; Pallen CJ; Dunn SE
Mol Cancer Ther; 2009 Nov; 8(11):3024-35. PubMed ID: 19887553
[TBL] [Abstract][Full Text] [Related]
15. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.
Chen XH; Lan B; Qu Y; Zhang XQ; Cai Q; Liu BY; Zhu ZG
World J Gastroenterol; 2006 Jan; 12(1):29-35. PubMed ID: 16440413
[TBL] [Abstract][Full Text] [Related]
17. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
Cheng MW; Wang BC; Weng ZQ; Zhu XW
Acta Histochem; 2012 Sep; 114(5):503-9. PubMed ID: 22000864
[TBL] [Abstract][Full Text] [Related]
20. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
